Marshall Wace
ELVN icon

Marshall Wace’s Enliven Therapeutics ELVN Stock Holding History

Marshall Wace’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27M Buy
+532,269
New +$22.6M 0.02% 598
2026
Q1 		– Sell
-371,906
Closed -$5.73M – 3328
2025
Q4 		$5.73M Buy
371,906
+31,424
+9% +$626K 0.01% 1092
2025
Q3 		$6.97M Buy
340,482
+7,149
+2% +$144K 0.01% 1061
2025
Q2 		$6.69M Buy
333,333
+322,173
+2,887% +$6.1M 0.01% 1013
2025
Q1 		$220K Sell
11,160
-30,222
-73% -$650K ﹤0.01% 2375
2024
Q4 		$931K Sell
41,382
-96,624
-70% -$2.5M ﹤0.01% 1766
2024
Q3 		$3.52M Sell
138,006
-54,094
-28% -$1.25M ﹤0.01% 1137
2024
Q2 		$4.49M Buy
+192,100
New +$4.04M 0.01% 1042

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Marshall Wace's ELVN Position: Q2 2026 in Review

Marshall Wace opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 532,269 shares worth $27M. The stake represents 0.02% of the portfolio and ranks #598 among its holdings. This is a return to the name: Marshall Wace previously reported a position in ELVN as recently as Q4 2025.

Marshall Wace first reported a position in ELVN in Q2 2024 and has held it in 8 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Marshall Wace held 532,269 shares of Enliven Therapeutics worth $27M as of Q2 2026.
  • Enliven Therapeutics was a new Marshall Wace position in Q2 2026.
  • Enliven Therapeutics made up 0.02% of Marshall Wace's portfolio in Q2 2026, its #598 holding.
  • Marshall Wace first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.